Phaseline

Targets › SSTR3

SSTR3 (Somatostatin receptor type 3): drug programs, companies and trials

17 programs from 17 companies in 47 trials: 26 Phase 2, 12 Phase 1, 5 Phase 3, 4 Phase 4; Oncology, Gastroenterology, Metabolic and endocrine; next expected readout Nov 2026.

Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. (UniProt, P32745)

Open in Phaseline: the race on SSTR3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University Hospital, AntwerpSomatostatin
Somatostatin receptor agonist
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 4Gastroenteropancreatic Neuroendocrine TumorApr 2029
Helsinki University Central HospitalPasireotide
Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 1 agonist
SSTR5, SSTR2, SSTR1, SSTR3Phase 4Pancreatic FistulaDec 2029
HTALutetium Oxodotreotide Lu-177
Somatostatin receptor binding agent
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 3NETS Ga68 Lu177Nov 2026
Advanced Accelerator ApplicationsLutetium Oxodotreotide Lu-177
Somatostatin receptor binding agent
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 3Gastro-enteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumors; Digestive System Neuroendocrine Tumor G1; Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) …Oct 2027
Sinotau Pharmaceutical GroupLutetium Oxodotreotide Lu-177
Somatostatin receptor binding agent
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 3Neuroendocrine TumorsDec 2028
Washington University School of MedicineSomatostatin
Somatostatin receptor agonist
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 3Neuroendocrine NeoplasmNov 2034
The Netherlands Cancer InstituteSomatostatin
Somatostatin receptor agonist
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 2Neuroendocrine TumorsJan 2027
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS177Lu-DOTATOC
Somatostatin receptor-targeted radionuclide therapy with lutetium-177
SSTR1, SSTR2, SSTR3, SSTR4, SSTR5Phase 2Neuroendocrine TumorsJan 2027
Memorial Sloan Kettering Cancer CenterPasireotide
Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 1 agonist
SSTR5, SSTR2, SSTR1, SSTR3Phase 2Prolactin-Producing Pituitary TumorFeb 2027
University of Alberta68Ga-HA-DOTATATE
Somatostatin receptor (SSR) PET imaging tracer - gallium-68 labeled somatostatin analog
SSTR1, SSTR2, SSTR3, SSTR5Phase 2Neuroendocrine TumorsAug 2027
Australasian Gastro-Intestinal Trials GroupSomatostatin
Somatostatin receptor agonist
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 2Neuroendocrine TumorsSep 2027
University Hospital HeidelbergPasireotide
Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 1 agonist
SSTR5, SSTR2, SSTR1, SSTR3Phase 2Desmoplastic Small Round Cell TumorOct 2027
CSPC ZhongQi Pharmaceutical TechnologyOctreotide
Somatostatin receptor agonist
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 2Gastroenteropancreatic Neuroendocrine Tumors; Pancreas Head CancerAug 2028
RECORDATI GROUPPasireotide Diaspartate
Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 1 agonist
SSTR5, SSTR2, SSTR1, SSTR3Phase 2Post-Bariatric Hypoglycemia–
RayzeBioRYZ401
Ac-225-based targeted alpha therapy for somatostatin receptor expression
SSTR1, SSTR2, SSTR3, SSTR4, SSTR5Phase 1GEP-NETFeb 2027
NovartisLutetium Oxodotreotide
Somatostatin receptor binding agent
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 1Glioblastoma; Extensive Stage Small Cell Lung CancerMay 2027
Jason WinnickSomatostatin
Somatostatin receptor agonist
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 1Hypoglycemia; IatrogenicMay 2028

Conditions

Neuroendocrine Tumors (11) Metastatic Pancreatic Neuroendocrine Tumor (3) Gastroenteropancreatic Neuroendocrine Tumor (2) Gastroenteropancreatic Neuroendocrine Tumors (2) Meningioma (2) Glioblastoma (1) Extensive Stage Small Cell Lung Cancer (1) Desmoplastic Small Round Cell Tumor (1) Neuroendocrine Neoplasm (1) Hypoglycemia; Iatrogenic (1) Pancreatic Fistula (1) NETS Ga68 Lu177 (1)

Modalities

small molecule (7), mixed (5), protein or peptide (5)

Companies

Novartis (1) University Hospital, Antwerp (1) University Hospital Heidelberg (1) Washington University School of Medicine (1) Sinotau Pharmaceutical Group (1) Jason Winnick (1) Helsinki University Central Hospital (1) University of Alberta (1) HTA (1) Memorial Sloan Kettering Cancer Center (1) Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) Australasian Gastro-Intestinal Trials Group (1) Advanced Accelerator Applications (1) CSPC ZhongQi Pharmaceutical Technology (1) RECORDATI GROUP (1) The Netherlands Cancer Institute (1) RayzeBio (1)

Related targets

SSTR5 (17) SSTR2 (17) SSTR1 (17) SSTR4 (12)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.